|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||136.00 - 138.96|
|52 Week Range||95.08 - 149.31|
|PE Ratio (TTM)||174.19|
|Earnings Date||Feb 21, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||147.17|
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.
Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
NEW YORK, Nov. 22, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM ...
Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.